

Oral contraceptive use and kidney cancer

Table S1. Sensitivity analyses: RRs, 95% CIs and *P* values after excluding each study

Excluded Study	RR ^a (95% CI)	I ² (%)	P
McCredie M	0.90 (0.82-0.99)	0	0.712
Mellemgaard A	0.89 (0.81-0.98)	0	0.625
Lindblad P	0.92 (0.83-1.01)	0	0.883
Chow HW	0.90 (0.82-0.98)	0	0.636
Gago-Dominguez M	0.87 (0.81-0.98)	0	0.664
Molokwu JC	0.89 (0.81-0.98)	0	0.633
Kabat GC	0.90 (0.82-0.99)	0	0.673
Zucchetto A	0.89 (0.81-0.98)	0	0.625
Setiawan VW	0.88 (0.80-0.97)	0	0.729
Lee JE	0.88 (0.80-0.97)	0	0.676
Purdue MP	0.88 (0.80-0.97)	0	0.795
Karami S	0.91 (0.81-1.02)	0	0.640

^aSummary RRs (95% CIs) were calculated using the fixed or random effects model based on the results of I²-statistics.

Table S2. Sensitivity analyses: RRs, 95% CIs and *P* values after excluding each study

Study removed	RR ^a (95% CI)	I ² (%)	p
Mellemgaard A	0.80 (0.68-0.94)	33.9	0.158
Lindblad P	0.83 (0.70-0.99)	7.4	0.373
Chow HW	0.81 (0.69-0.96)	9.9	0.354
Gago-Dominguez M	0.77 (0.65-0.91)	9.9	0.353
Kabat GC	0.80 (0.67-0.95)	33.9	0.158
Setiawan VW	0.78 (0.65-0.92)	27.7	0.208
Lee JE	0.79 (0.66-0.94)	33.0	0.165
Purdue MP	0.78 (0.66-0.92)	26.2	0.219
Karami S	0.84 (0.69-1.02)	28.7	0.199

^aSummary RRs (95% CIs) were calculated using the fixed or random effects model based on the results of I²-statistics.